结直肠癌筛查试验(TARGET-C)中结肠镜、粪便免疫化学检测与风险适应筛查策略的比较
TARGET-C试验将19373名参与者按1:2:2随机分配至一次性结肠镜组(n=3883)、年度粪便免疫化学检测(FIT)组(n=7793)和年度风险适应筛查组(n=7697),FIT组与风险适应组各进行3轮筛查,随访3年。意向性分析显示三组进展期肿瘤检出率分别为2.76%、2.17%和2.35%,组间比较均未达统计学显著。作者认为风险适应策略是人群结直肠癌筛查中可行且成本有利的策略,可补充一次性结肠镜和年度重复FIT筛查。
要点
- 结肠镜组、FIT组和风险适应组3轮筛查的参与率分别为42.4%、99.3%和89.2%。
- 意向性分析进展期肿瘤检出率:结肠镜组2.76%、FIT组2.17%、风险适应组2.35%,组间比较均未达统计学显著。
- 每检出1例进展期肿瘤所需结肠镜数分别为15.4、7.8和10.2次,政府视角打包付费下每检出1例进展期肿瘤的成本分别为6928元人民币(1004美元)、5821元人民币(844美元)和6694元人民币(970美元)。
核心结论
- 作者认为风险适应筛查策略是人群结直肠癌筛查中可行且成本有利的策略,可补充已经确立的一次性结肠镜和年度重复FIT筛查策略。
研究设计与样本
- TARGET-C试验将19373名参与者按1:2:2随机分配至一次性结肠镜组(n=3883)、年度FIT组(n=7793)和年度风险适应筛查组(n=7697),后两组各进行3轮筛查,并在3年研究期内对所有参与者随访健康结局。
- 风险适应筛查组依据风险分层评分,高风险参与者转诊结肠镜,低风险参与者转诊FIT。
- 主要结局为进展期结直肠肿瘤(结直肠癌和进展期癌前病变)检出率;试验注册于中国临床试验注册中心(注册号:ChiCTR1800015506)。
主要发现
- 结肠镜组、FIT组和风险适应筛查组3轮筛查的参与率分别为42.4%、99.3%和89.2%。
- 意向性分析进展期肿瘤检出率:结肠镜组2.76% vs FIT组2.17%,OR 1.27(95%CI 0.99-1.63;P=.056);结肠镜组2.76% vs 风险适应筛查组2.35%,OR 1.17(95%CI 0.91-1.49;P=.218);风险适应筛查组2.35% vs FIT组2.17%,OR 1.09(95%CI 0.88-1.35;P=.438)。
- 每检出1例进展期肿瘤所需结肠镜数:结肠镜组15.4次、FIT组7.8次、风险适应筛查组10.2次。
- 政府视角打包付费下每检出1例进展期肿瘤的成本:结肠镜组6928元人民币(1004美元)、FIT组5821元人民币(844美元)、风险适应筛查组6694元人民币(970美元)。
临床怎么用
- 作者认为风险适应筛查策略是人群结直肠癌筛查中可行且成本有利的策略,可补充一次性结肠镜和年度重复FIT筛查策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The screening yield and related cost of a risk-adapted screening approach compared with established screening strategies in population-based colorectal cancer (CRC) screening are not clear. METHODS: We randomly allocated 19,373 participants into 1 of the 3 screening arms in a 1:2:2 ratio: (1) one-time colonoscopy (n = 3883); (2) annual fecal immunochemical test (FIT) (n = 7793); (3) annual risk-adapted screening (n = 7697), in which, based on the risk-stratification score, high-risk participants were referred for colonoscopy and low-risk ones were referred for FIT. Three consecutive screening rounds were conducted for both the FIT and the risk-adapted screening arms. Follow-up to trace the health outcome for all the participants was conducted over the 3-year study period. The detection rate of advanced colorectal neoplasia (CRC and advanced precancerous lesions) was the main outcome. The trial was registered in the Chinese Clinical Trial Registry (number: ChiCTR1800015506). RESULTS: In the colonoscopy, FIT, and risk-adapted screening arms over 3 screening rounds, the participation rates were 42.4%, 99.3%, and 89.2%, respectively; the detection rates for advanced neoplasm (intention-to-treat analysis) were 2.76%, 2.17%, and 2.35%, respectively, with an odds ratio (OR)colonoscopy vs FIT of 1.27 (95% confidence interval [CI]: 0.99-1.63; P = .056), an ORcolonoscopy vsrisk-adapted screening of 1.17 (95% CI, 0.91-1.49; P = .218), and an ORrisk-adapted screeningvs FIT of 1.09 (95% CI, 0.88-1.35; P = .438); the numbers of colonoscopies needed to detect 1 advanced neoplasm were 15.4, 7.8, and 10.2, respectively; the costs for detecting 1 advanced neoplasm from a government perspective using package payment format were 6928 Chinese Yuan (CNY) ($1004), 5821 CNY ($844), and 6694 CNY ($970), respectively. CONCLUSIONS: The risk-adapted approach is a feasible and cost-favorable strategy for population-based CRC screening and therefore could complement the well-established one-time colonoscopy and annual repeated FIT screening strategies. (Chinese Clinical Trial Registry; ChiCTR1800015506).
引用
- Chen H, Shi J, Lu M, et al. Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-Adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C). Clin Gastroenterol Hepatol. 2022. PMID: 35964896. doi:10.1016/j.cgh.2022.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。